Kimberly A. Robell

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Nelson Rhodes, Dirk A. Heerding, Derek R. Duckett et al. · Cancer Research · 2008 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

Kiranmai Gumireddy, Stacey J. Baker, Stephen C. Cosenza et al. · Proceedings of the National Academy of Sciences · 2005 · 221 citations · Full text

Medicine, Molecular Biology, Oncology +15

Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor

Melissa Dumble, Ming‐Chih Crouthamel, Shuyun Zhang et al. · PLoS ONE · 2014 · 144 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (<i>E</i>)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity

M. V. Ramana Reddy, Muralidhar R. Mallireddigari, Venkat R. Pallela et al. · Journal of Medicinal Chemistry · 2011 · 95 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation.

Ecaterina E. Dumbrava, Melissa L. Johnson, Anthony W. Tolcher et al. · Journal of Clinical Oncology · 2022 · 81 citations

Medicine, Oncology, Pharmacology +9